<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493061</url>
  </required_header>
  <id_info>
    <org_study_id>HAI-CRCLM</org_study_id>
    <nct_id>NCT03493061</nct_id>
  </id_info>
  <brief_title>A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM</brief_title>
  <official_title>Systemic Chemotherapy With Irinotecan Plus Hepatic Arterial Infusion With Floxuridine and Oxaliplatin in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to optimize response rates and rates of secondary resections of&#xD;
      metastases in patients with initially non-resectable metastatic colorectal cancer Liver&#xD;
      Metastasis. The patients will be treated with systemic chemotherapy With irinotecan plus&#xD;
      hepatic arterial infusion With floxuridine and oxaliplatin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies and our experience have proved the efficacy and safety of systemic&#xD;
      chemotherapy combined with hepatic arterial infusion (HAI) with floxuridine and dexamethasone&#xD;
      in patients with initially unresectable colorectal liver metastasis. Hepatic arterial&#xD;
      infusion oxaliplatin trials have been done with oxaliplatin alone and in combination with&#xD;
      irinotecan, 5-FU/LV, and mitomycin-C and have showed that Hepatic arterial infusion&#xD;
      oxaliplatin could increase response rate and resection rate for colorectal liver metastasis.&#xD;
      Therefore, we designed this study to determine whether systemic chemotherapy With irinotecan&#xD;
      plus hepatic arterial infusion With floxuridine and oxaliplatin can increase the complete&#xD;
      resection rate (R0) and improve the overall survival in patients with initially unresectable&#xD;
      colorectal liver metastasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete resection rates (R0 resection rates)</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as no macroscopic or microscopic residual tumor</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Systemic CPT-11 + HAI (FUDR+L-OHP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:&#xD;
Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.&#xD;
then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.&#xD;
This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15</description>
    <arm_group_label>Systemic CPT-11 + HAI (FUDR+L-OHP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.</description>
    <arm_group_label>Systemic CPT-11 + HAI (FUDR+L-OHP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <description>0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.</description>
    <arm_group_label>Systemic CPT-11 + HAI (FUDR+L-OHP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years old&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
          -  Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis&#xD;
&#xD;
          -  Initially unresectable colorectal liver metastasis confirmed by the multidisciplinary&#xD;
             team (MDT)&#xD;
&#xD;
          -  With no prior treatment for liver metastasis, including chemotherapy, operation,&#xD;
             radiotherapy, transcatheter hepatic arterial chemoembolization (TACE) and targeted&#xD;
             therapy&#xD;
&#xD;
          -  Without extra-hepatic metastasis confirmed by CT, MRI or PET/CT (if necessary)&#xD;
             scanning&#xD;
&#xD;
          -  With adequate bone marrow function: platelets ≥ 90 x 109/L; white blood cells ≥&#xD;
             3×109/L; absolute neutrophil count (ANC) ≥ 1.5 x 109/L Serum bilirubin ≤ 1.5 x ULN,&#xD;
             AST and ALT ≤ 5 x ULN&#xD;
&#xD;
          -  Patient has no ascites and with adequate blood coagulation function, albumin ≥ 35 g/L&#xD;
&#xD;
          -  Grade A level of Child-Push Liver Function&#xD;
&#xD;
          -  Creatinine ≤ 1× ULN, or Calculated Creatinine Clearance &gt;50ml/min （Cockcroft-Gault&#xD;
             Equation）&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or&#xD;
             could not afford it)&#xD;
&#xD;
          -  Patients have provided a signed Informed Consent Form&#xD;
&#xD;
          -  With good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With any extra-hepatic metastasis and/or primary tumor recurrence&#xD;
&#xD;
          -  Severe arterial embolism or ascites&#xD;
&#xD;
          -  With hemorrhagic tendency or coagulation disorders&#xD;
&#xD;
          -  Hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Severe and uncontrolled systemic complications such as infections or diabetes.&#xD;
&#xD;
          -  Serious cardiovascular diseases such as cerebrovascular accident (within 6 months&#xD;
             before enrollment), myocardial infarction (within 6 months before enrollment),&#xD;
             uncontrolled hypertension even with appropriate drug intervention, unstable angina&#xD;
             pectoris, congestive heart failure (NYHA 2-4 degree), arrhythmia that needs medication&#xD;
             intervention&#xD;
&#xD;
          -  Patient who has suffered from central nervous system diseases such as primary brain&#xD;
             tumor, uncontrolled epilepsy even with standard treatment, any brain metastasis or&#xD;
             stroke&#xD;
&#xD;
          -  Patient who has a concurrent malignancy or has a malignancy within 5 years before&#xD;
             study enrollment, (with the exception of radically resected skin basal cell carcinoma&#xD;
             or cervical carcinoma in situ)&#xD;
&#xD;
          -  Patient who has received any investigational antineoplastic agent within 28 days&#xD;
             before the enrollment&#xD;
&#xD;
          -  Any residual toxicity from prior chemotherapy (with the exception of alopecia), such&#xD;
             as grade 2 or more sensory peripheral neuropathy (NCI CTC v3.0), oxaliplatin-based&#xD;
             regimen will not be considered&#xD;
&#xD;
          -  Patient who is allergic to oxaliplatin, leucovorin, 5-Fluorouracil, floxuridine or&#xD;
             dexamethasone&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patient who does not use or refuses to take any appropriate contraceptive measures&#xD;
             (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel&#xD;
             or sterilization operation), including women of childbearing age (within 2 years after&#xD;
             the last menstrual period) and men who are with possible fertility&#xD;
&#xD;
          -  Unable or unwilling to comply with the research plan&#xD;
&#xD;
          -  The existence of any other disease, dysfunction caused by metastatic lesions, or&#xD;
             suspicious disease found on the regular examination, which indicating&#xD;
             contraindications to the use of study drugs or may bring high risks of treatment&#xD;
             related complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yuhong, MD</last_name>
      <phone>020-87342487</phone>
      <email>liyh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Yuhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>October 27, 2019</last_update_submitted>
  <last_update_submitted_qc>October 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Yuhong Li</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

